Expression and antigenic epitopes mapping of receptor binding domain on the spike protein of severe acute respiratory syndrome coronavirus

Progress in Biochemistry and Biophysics

Volumn 32, Issue 11, 2005, Pages 1030-1037

  Hua, Rong Hong ^a   Tong, Guang Zhi ^a   Wang, Yun Feng ^a   Zhou, Yan Jun ^a  

^a INSTITUTE OF PLANT PROTECTION   (China)

Author keywords

Epitope; Severe acute respiratory syndrome (SARS CoV); Spike protein

Indexed keywords

CORONAVIRUS; SARS CORONAVIRUS;

EID: 31144458970     PISSN: 10003282     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Peiris J S, Lai S T, Poon L L, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet, 2003, 361 (9366): 1319-1325
2. Drosten C, Gunther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med, 2003, 348 (20): 1967-1976
3. Ksiazek T G, Erdman D, Goldsmith C S, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med, 2003, 348 (20): 1953-1966
4. Gallagher T M, Buchmeier M J. Coronavirus spike proteins in viral entry and pathogenesis. Virology, 2001, 279 (2): 371-374
5. Hofmann H, Pohlmann S. Cellular entry of the SARS coronavirus. Trends Microbiol, 2004, 12 (10): 466-472
6. Li W, Moore M J, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature, 2003, 426 (6965): 450-454
7. Wang P, Chen J, Zheng A, et al. Expression cloning of functional receptor used by SARS coronavirus. Biochem Biophys Res Commun, 2004, 315 (2): 439-444
8. Babcock G J, Esshaki D J, Thomas W D Jr, et al. Amino acids 270 to 510 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction with receptor. J Virol, 2004, 78 (9): 4552-4560
9. Wong S K, Li W, Moore M J, et al. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J Biol Chem, 2004, 279 (5): 3197-3201
10. Xiao X, Chakraborti S, Dimitrov A S, et al. The SARS-CoV S glycoprotein: expression and functional characterization. Biochem Biophys Res Commun, 2003, 312 (4): 1159-1164
11. Hua R, Zhou Y, Wang Y, et al. Identification of two antigenic epitopes on SARS-CoV spike protein. Biochem Biophys Res Commun, 2004, 319 (3): 929-935
12. He Y, Zhou Y, Liu S, et al. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem Biophys Res Commun, 2004, 324 (2): 773-781
13. Daniel C, Anderson R, Buchmeier M J, et al. Identification of an immunodominant linear neutralization domain on the S2 portion of the murine coronavirus spike glycoprotein and evidence that it forms part of complex tridimensional structure. J Virol, 1993, 67 (3): 1185-1194
14. Daniel C, Lacroix M, Talbot P J. Mapping of linear antigenic sites on the S glycoprotein of a neurotropic murine coronavirus with synthetic peptides: a combination of nine prediction algorithms fails to identify relevant epitopes and peptide immunogenicity is drastically influenced by the nature of the protein carrier. Virology, 1994, 202 (2): 540-549
15. Koolen M J, Borst M A, Horzinek M C, et al. Immunogenic peptide comprising a mouse hepatitis virus A59 B-cell epitope and an influenza virus T-cell epitope protects against lethal infection. J Virol, 1990, 64 (12): 6270-6273
16. Luytjes W, Geerts D, Posthumus W, et al. Amino acid sequence of a conserved neutralizing epitope of murine coronaviruses. J Virol, 1989, 63 (3): 1408-1412
17. Talbot P J, Buchmeier M J. Antigenic variation among murine coronaviruses: evidence for polymorphism on the peplomer glycoprotein, E2. Virus Res, 1985, 2 (4): 317-328
18. Talbot P J, Salmi A A, Knobler R L, et al. Topographical mapping of epitopes on the glycoproteins of murine hepatitis virus-4 (strain JHM): correlation with biological activities. Virology, 1984, 132 (2): 250-260
19. Koo M, Bendahmane M, Lettieri G A, et al. Protective immunity against murine hepatitis virus (MHV) induced by intranasal or subcutaneous administration of hybrids of tobacco mosaic virus that carries an MHV epitope. Proc Natl Acad Sci USA, 1999, 96 (14): 7774-7779
20. Yu M W, Scott J K, Fournier A, et al. Characterization of murine coronavirus neutralization epitopes with phage-displayed peptides. Virology, 2000, 271 (1): 182-196